[go: up one dir, main page]

PE20020385A1 - Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada - Google Patents

Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada

Info

Publication number
PE20020385A1
PE20020385A1 PE2001000770A PE2001000770A PE20020385A1 PE 20020385 A1 PE20020385 A1 PE 20020385A1 PE 2001000770 A PE2001000770 A PE 2001000770A PE 2001000770 A PE2001000770 A PE 2001000770A PE 20020385 A1 PE20020385 A1 PE 20020385A1
Authority
PE
Peru
Prior art keywords
eletriptan
core
weight
composition
hours
Prior art date
Application number
PE2001000770A
Other languages
English (en)
Inventor
Raspide Manaud Pierre Frederic De
Mathias Walther
Ross James Macrae
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20020385A1 publication Critical patent/PE20020385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electroluminescent Light Sources (AREA)
  • Luminescent Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN NUCLEO DE ELETRIPTAN 3-{[1-METILPIRROLIDIN-2(R)-IL]METIL}-5-(2-FENILSULFONILETIL)1H-INDOL Y b) COADYUVANTES DE EXTRUSION, AGLUTINANTES, DILUYENTES. EL NUCLEO ESTA REVESTIDO CON UNO O MAS COPOLIMEROS ACRILICOS CON GRUPOS DE METACRILATO DE TRIMETILAMINOETILO. EL NUCLEO CONTIENEN HIDROBROMURO DE ELETRIPTAN, HEMISULFATO DE ELETRIPTAN CUYO DIAMETRO ES DE 0,2 mm A 2 mm Y CONTIENE DE 10% A 90% PESO/PESO DE ELETRIPTAN. SE REFIERE TAMBIEN A UNA COMPOSICION EN LA CUAL SE HA INSERTADO UNA CAPA PROTECTORA ADICIONAL ENTRE EL NUCLEO Y EL REVESTIMIENTO, PERMEABLE E INSOLUBLE EN AGUA SELECCIONADA DE HIDROXIPROPILMETILCELULOSA CON UN GROSOR DE 10 MICROMETROS A 100 MICROMETROS. LA COMPOSICION ES CAPAZ DE SUMINISTRAR ELETRIPTAN EN UNA SOLUCION TAMPONADA A pH 7,5 SIENDO DICHA COMPOSICION CAPAZ DE CONSEGUIR UN CURSO SIGMOIDEO DE LIBERACION CONTROLADA DEL FARMACO EN EL CUAL: a) 5% EN PESO DEL FARMACO HA SIDO LIBERADO EN UN PUNTO TEMPORAL DE 1,5 A 12 HORAS DESPUES DE LA ADICION; b) 50% EN PESO DEL FARMACO HA SIDO LIBERADO EN UN PUNTO TEMPORAL DE 5 A 15 HORAS DESPUES DE LA ADICON Y c) EL 80% EN PESO DEL FARMACO HA SIDO LIBERADO DE 6,5 A 20 HORAS DESPUES DE LA ADICION Y PROPORCIONA UNA CONCENTRACION PLASMATICA MEDIA DE ELETRIPTAN SUPERIOR A 10 ng/ml A LAS 20 HORAS DESPUES DE LA ADMINISTRACION. LA COMPOSICION ES AGONISTA DEL RECEPTOR 5-HT 1B/1D Y PUEDER SER USADA EN EL TRATAMIENTO DE MIGRANA
PE2001000770A 2000-08-02 2001-08-01 Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada PE20020385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition

Publications (1)

Publication Number Publication Date
PE20020385A1 true PE20020385A1 (es) 2002-05-11

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000770A PE20020385A1 (es) 2000-08-02 2001-08-01 Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada

Country Status (38)

Country Link
US (1) US20020034545A1 (es)
EP (1) EP1365748B1 (es)
JP (1) JP2004505034A (es)
KR (1) KR20030024820A (es)
CN (1) CN1630511A (es)
AP (1) AP2001002233A0 (es)
AR (1) AR030099A1 (es)
AT (1) ATE308978T1 (es)
AU (1) AU2001270932A1 (es)
BG (1) BG107361A (es)
BR (1) BR0112839A (es)
CA (1) CA2417887C (es)
CZ (1) CZ2003241A3 (es)
DE (1) DE60114887T2 (es)
EA (1) EA200300110A1 (es)
EC (1) ECSP034451A (es)
EE (1) EE200300051A (es)
ES (1) ES2250429T3 (es)
GB (1) GB0018968D0 (es)
GT (1) GT200100149A (es)
HR (1) HRP20030036A2 (es)
HU (1) HUP0301453A2 (es)
IL (1) IL153494A0 (es)
IS (1) IS6649A (es)
MA (1) MA26934A1 (es)
MX (1) MXPA03000999A (es)
NO (1) NO20030498D0 (es)
NZ (1) NZ522976A (es)
OA (1) OA12348A (es)
PA (1) PA8523101A1 (es)
PE (1) PE20020385A1 (es)
PL (1) PL359847A1 (es)
SK (1) SK1082003A3 (es)
SV (1) SV2002000574A (es)
TN (1) TNSN01115A1 (es)
UY (1) UY26861A1 (es)
WO (1) WO2002009675A1 (es)
ZA (1) ZA200300868B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
AU2003294520A1 (en) * 2002-12-16 2004-07-09 Chx Technologies, Inc. Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
BRPI0409127A (pt) * 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
PL1915137T3 (pl) 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
DE602007012236D1 (de) 2006-04-26 2011-03-10 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
CA2694440A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
JP5907881B2 (ja) * 2009-11-16 2016-04-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ 固体（メタ）アクリレートコポリマーの分散剤による分散形態への変換方法
BR112017004552A2 (pt) * 2014-09-09 2017-12-05 Charleston Laboratories Inc composições farmacêuticas
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
DE60114887T2 (de) 2006-07-20
SK1082003A3 (en) 2004-09-08
MXPA03000999A (es) 2003-06-09
ECSP034451A (es) 2003-03-10
PA8523101A1 (es) 2002-08-26
SV2002000574A (es) 2002-12-02
CN1630511A (zh) 2005-06-22
WO2002009675A1 (en) 2002-02-07
IL153494A0 (en) 2003-07-06
JP2004505034A (ja) 2004-02-19
NO20030498L (no) 2003-01-31
ATE308978T1 (de) 2005-11-15
CA2417887C (en) 2006-11-14
EP1365748B1 (en) 2005-11-09
GT200100149A (es) 2002-06-25
EA200300110A1 (ru) 2003-06-26
AR030099A1 (es) 2003-08-13
EP1365748A2 (en) 2003-12-03
DE60114887D1 (de) 2005-12-15
ES2250429T3 (es) 2006-04-16
ZA200300868B (en) 2004-04-16
KR20030024820A (ko) 2003-03-26
HUP0301453A2 (hu) 2003-08-28
NZ522976A (en) 2004-11-26
WO2002009675A9 (en) 2003-09-18
MA26934A1 (fr) 2004-12-20
BG107361A (bg) 2003-06-30
PL359847A1 (pl) 2004-09-06
NO20030498D0 (no) 2003-01-31
HRP20030036A2 (en) 2003-04-30
US20020034545A1 (en) 2002-03-21
CZ2003241A3 (cs) 2004-02-18
EE200300051A (et) 2004-10-15
OA12348A (en) 2004-03-19
UY26861A1 (es) 2002-02-28
TNSN01115A1 (fr) 2005-11-10
IS6649A (is) 2002-12-05
AU2001270932A1 (en) 2002-02-13
AP2001002233A0 (en) 2001-09-30
CA2417887A1 (en) 2002-02-07
BR0112839A (pt) 2003-06-24
GB0018968D0 (en) 2000-09-20

Similar Documents

Publication Publication Date Title
PE20020385A1 (es) Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
RU2008117432A (ru) Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
DE602005016532D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
EA200701575A1 (ru) Формуляция леветирацетама длительного высвобождения
DK1246622T3 (da) Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse
DE602005015686D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
AR042536A1 (es) Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
BRPI0410653A (pt) composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
HRP20100664T1 (hr) Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
GEP20125684B (en) Dipeptidyl peptidase inhibitors weekly administration
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
Cohen et al. 5-Hydroxytryptamine1F receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin1F receptor agonist in rabbit saphenous vein
HRP20010342B1 (en) Pharmaceutical composition for modified release insulin sensitiser
ITMI20041628A1 (it) Sistema terapeutico a rilascio controllato per uso topico transdermico
DE60035579D1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
AR065077A1 (es) Composiciones farmaceuticas y metodos para utilizar temozolomida e inhibidores de quinasa multidirigidos
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern

Legal Events

Date Code Title Description
FC Refusal